A Phase 1 interventional study of PD-0332991 in Neoplasms and Lymphoma, Non-Hodgkin, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-05.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Lymphoma, Non-Hodgkin by Pfizer — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Pfizer.
Among the 29 studies in Lymphoma, Non-Hodgkin by Pfizer, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2004, is one of 16 in phase 1, and was the 3rd registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →None of the 29 studies in Lymphoma, Non-Hodgkin by Pfizer is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 66 across the 28 interventional studies. Of the 28 that completed or were terminated, 12 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Lymphoma, Non-Hodgkin by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
This study's enrollment of 74 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PD-0332991
Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
Number of Participants With Dose-Limiting Toxicities (DLT)
DLT: an adverse event occurring after initiation of PD 0332991 that met any following criteria: 1) Grade 4 hematologic toxicity (platelets less than \[\<\] 25000 per microliter (mcL), absolute neutrophil count \[ANC\] \<500/mcL, hemoglobin \[Hb\] \<6.5 gram per deciliter \[g/dL\]; 2) ANC \<1000/mcL associated with documented infection or fever greater than or equal to (\>=) 38.5 degrees Celsius; 3) \>=Grade 3 non-hematologic treatment-related toxicity. In an asymptomatic participant, Grade 3 corrected QT (QTc) prolongation (\>500 millisecond) (only if persisted with repeat testing and after correction of reversible causes \[electrolyte abnormalities or hypoxia\]); and 4) Inability to receive next dose of PD 0332991 within 1 week (+/-1 day) of last dose due to lack of hematologic recovery (platelets \<50000/mcL, ANC \<1000/mcL, and Hb \<8.0 g/dL) or due to prolonged non-hematologic toxicities of \>=Grade 3 severity. Occurrence of a DLT necessitated immediate interruption of scheduled study treatment.
Time frame: Baseline up to 28 days
Maximum Administered Dose (MAD)
Three new evaluable participants were to be assessed at each new dose level. The minimum time that these participants were to be followed after starting treatment was 1 cycle (28 or 21 days) before a new dose level could be opened. If none of these 3 participants experienced a DLT, the next higher dose level was to be opened on that schedule. If 1 participant developed a DLT, 3 more evaluable participants were to be enrolled at that dose level; if none of these additional 3 participants developed a DLT, the next higher dose level was to be opened on that schedule. If \>=2 participants experienced a first cycle DLT at the same dose level and schedule, that dose level was to be defined as the MAD for that schedule. No additional participants were to be entered at the MAD for that dosing schedule. DLT is defined in Outcome Measure 1.
Time frame: Baseline up to 28 days
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)
MTD was defined as the highest dose level studied for which the incidence of first cycle DLT was \<33%. Once MTD was determined, it was defined as RP2D. DLT is defined in Outcome Measure 1.
Time frame: Baseline up to 28 days
Number of Dose-Limiting Toxicities (DLTs) Categorized as Per the Nature
DLT is defined in Outcome Measure 1. Hematologic (Grade 4 \[life-threatening or disabling\]) and non-hematologic (Grade 3 \[severe\], 4 \[life-threatening and disabling\], 5 \[resulting in death\]) DLTs are reported separately. A single participant may experience more than one DLT. Both treatment-related and treatment-unrelated DLT events were reported for this outcome measure.
Time frame: Baseline up to 28 days
Number of Participants With Treatment Emergent Adverse Events Categorized by Severity
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. For clinical description of nature (severity) of AEs, AEs were grades as: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening or disabling AE; and Grade 5: death related to AE. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.
Time frame: Cycle 1, Cycle 2 up to 28 days after end of treatment (up to Cycle 93)
Number of Participants With Treatment-Related Treatment Emergent Adverse Events
A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.
Time frame: Cycle 1, Cycle 2 up to 28 days after end of treatment (up to Cycle 93)
Number of Participants Who Died Due to Adverse Event on the Basis of Relatedness to Study Drug
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness \[to study drug\] was assessed by the investigator (Yes/No).
Time frame: Baseline up to 30 days after end of treatment (up to Cycle 93)
Maximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Maximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Maximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
The mean Cmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Maximum Observed Plasma Concentration (Cmax) on Day 1: Food Effect
To determine the impact of food (specifically a high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In this crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. The first 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, the next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. The high-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of the total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
The median Tmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Food Effect
To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Terminal Half-life (t½ ) on Day 1: Single Dose
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Terminal Half-life (t½ ) on Day 8: Multiple Dose
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Terminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Terminal half-life is the time measured for the plasma concentration to decrease by one half. The mean t1/2 for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Terminal Half-life (t½ ) on Day 1: Food Effect
To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The mean AUClast for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Food Effect
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Area Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Area under the curve from time zero to end of the dosing interval (24 hours) \[AUC (0-tau)\]. The mean AUC (0-tau) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Single Dose
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 8: Multiple Dose
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Food Effect
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Apparent Oral Clearance (CL/F) on Day 1: Single Dose
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Apparent Oral Clearance (CL/F) on Day 8: Multiple Dose
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Apparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. The mean CL/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Apparent Oral Clearance (CL/F) on Day 1: Food Effect
Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Apparent Volume of Distribution (Vz/F) on Day 1: Single Dose
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Apparent Volume of Distribution (Vz/F) on Day 8: Multiple Dose
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Apparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. The mean Vz/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Apparent Volume of Distribution (Vz/F) on Day 1: Food Effect
Volume of distribution: theoretical volume in which total amount of drug would need to be uniformly distributed to produce desired plasma concentration. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Accumulation Ratio (Rac) on Day 8: Multiple Dose
Rac at Day 8 = AUC (0-tau) at Day 8 divided by AUC (0-tau) at Day 1.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10, and 24 hours post-dose on C1D1 and C1D8
Accumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Rac at Day 14/21 = AUC (0-tau) at Day 14/21 divided by AUC (0-tau) at Day 1. The mean Rac for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Terminal Phase Rate Constant [Lambda (z)] on Day 1: Single Dose
Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural--logarithm transformed concentration--time profile.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Terminal Phase Rate Constant [Lambda (z)] on Day 8: Multiple Dose
Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Terminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile. The mean lambda (z) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Terminal Phase Rate Constant [Lambda (z)] on Day 1: Food Effect
Terminal phase rate constant: absolute value of slope of a linear regression during terminal phase of natural-logarithm transformed concentration-time profile. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose
Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Urine PK analysis was performed only in the MTD/RP2D groups (125 mg \[21/28 Days\] and 200 mg \[14/21 Days\]).
Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1
Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Food Effect
The Ae is defined in Outcome Measure 42. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1
Percent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose
Percent of dose recovered unchanged in urine over the 10 hour collection interval=100\*(Ae divided by dose). Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval.
Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1
Percent Dose Recovered Unchanged (Percent Ae) in Urine: Food Effect
The percent Ae is defined in Outcome Measure 44. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1
Number of Participants With Best Response
Number of participants with best response. Complete response (CR): disappearance of all target and non-target lesions. Partial Response (PR): \>=30% decrease in sum of longest diameter (LD) of lesions taking as reference baseline sum LD and no unequivocal progression in non-target lesions. Progressive disease (PD): \>=20% increase in sum of LD of lesions taking as a reference smallest sum of the LD since treatment start, or the appearance of \>=1 new lesion or unequivocal progression of existing non-target lesions. Stable disease (SD): neither shrinkage for PR nor increase for PD taking as reference smallest sum of LD since treatment start. SD was assessed following the first 2 cycles of treatment (\>=2 cycles), 4 cycles of treatment (\>=4 cycles), and 10 cycles of treatment (\>=10 cycles). Participants may be reported in more than 1 category of SD. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
Time frame: Baseline up to end of treatment, assessed at C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)
Inhibition of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) Based on Phosphorylated Retinoblastoma (p-Rb) in Tumor Tissue
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue and p-Rb levels (fold decrease) were to be reported.
Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)
Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With PD 0322991 Dose
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with respect to PD 0322991 dose.
Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)
Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Exposure
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with PD 0322991 exposure.
Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)
Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Tumor Response
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with tumor response.
Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)
| Milestone | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 7 | 3 | 22 | 3 | 3 | 4 | 20 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 7 | 3 | 22 | 3 | 3 | 4 | 20 | 6 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Progressive disease | 2 | 3 | 6 | 2 | 15 | 2 | 3 | 3 | 15 | 6 |
| Withdrew: Transitioned | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
DLT: an adverse event occurring after initiation of PD 0332991 that met any following criteria: 1) Grade 4 hematologic toxicity (platelets less than \[\<\] 25000 per microliter (mcL), absolute neutrophil count \[ANC\] \<500/mcL, hemoglobin \[Hb\] \<6.5 gram per deciliter \[g/dL\]; 2) ANC \<1000/mcL associated with documented infection or fever greater than or equal to (\>=) 38.5 degrees Celsius; 3) \>=Grade 3 non-hematologic treatment-related toxicity. In an asymptomatic participant, Grade 3 corrected QT (QTc) prolongation (\>500 millisecond) (only if persisted with repeat testing and after correction of reversible causes \[electrolyte abnormalities or hypoxia\]); and 4) Inability to receive next dose of PD 0332991 within 1 week (+/-1 day) of last dose due to lack of hematologic recovery (platelets \<50000/mcL, ANC \<1000/mcL, and Hb \<8.0 g/dL) or due to prolonged non-hematologic toxicities of \>=Grade 3 severity. Occurrence of a DLT necessitated immediate interruption of scheduled study treatment.
| participants | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLT) | 0 | 0 | 2 | 0 | 1 | 2 | 0 | 0 | 4 | 3 |
Three new evaluable participants were to be assessed at each new dose level. The minimum time that these participants were to be followed after starting treatment was 1 cycle (28 or 21 days) before a new dose level could be opened. If none of these 3 participants experienced a DLT, the next higher dose level was to be opened on that schedule. If 1 participant developed a DLT, 3 more evaluable participants were to be enrolled at that dose level; if none of these additional 3 participants developed a DLT, the next higher dose level was to be opened on that schedule. If \>=2 participants experienced a first cycle DLT at the same dose level and schedule, that dose level was to be defined as the MAD for that schedule. No additional participants were to be entered at the MAD for that dosing schedule. DLT is defined in Outcome Measure 1.
| milligram | PD 0332991 (21/28 Days) | PD 0332991 (14/21 Days) |
|---|---|---|
| Maximum Administered Dose (MAD) | 150 | 225 |
MTD was defined as the highest dose level studied for which the incidence of first cycle DLT was \<33%. Once MTD was determined, it was defined as RP2D. DLT is defined in Outcome Measure 1.
| milligram | PD 0332991 (21/28 Days) | PD 0332991 (14/21 Days) |
|---|---|---|
| Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D) | 125 | 200 |
DLT is defined in Outcome Measure 1. Hematologic (Grade 4 \[life-threatening or disabling\]) and non-hematologic (Grade 3 \[severe\], 4 \[life-threatening and disabling\], 5 \[resulting in death\]) DLTs are reported separately. A single participant may experience more than one DLT. Both treatment-related and treatment-unrelated DLT events were reported for this outcome measure.
| DLTs | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Hematologic DLT: Grade 4 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Non-Hematologic DLT: Grade 3 | 0 | 0 | 2 | 0 | 5 | 0 | 0 | 0 | 3 | 1 |
| Non-Hematologic DLT: Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Non-Hematologic DLT: Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. For clinical description of nature (severity) of AEs, AEs were grades as: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening or disabling AE; and Grade 5: death related to AE. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.
| participants | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 TEAEs: Grade 1 | 0 | 2 | 1 | 0 | 7 | 1 | 2 | 2 | 6 | 1 |
| Cycle 1 TEAEs: Grade 2 | 1 | 1 | 2 | 1 | 5 | 0 | 0 | 1 | 6 | 1 |
| Cycle 1 TEAEs: Grade 3 | 0 | 0 | 3 | 2 | 7 | 1 | 0 | 0 | 8 | 2 |
| Cycle 1 TEAEs: Grade 4 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 1 |
| Cycle 1 TEAEs: Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Post Cycle 1 TEAEs: Grade 1 | 0 | 0 | 1 | 0 | 8 | 0 | 0 | 1 | 3 | 1 |
| Post Cycle 1 TEAEs: Grade 2 | 0 | 3 | 1 | 2 | 3 | 1 | 1 | 1 | 4 | 1 |
| Post Cycle 1 TEAEs: Grade 3 | 2 | 0 | 2 | 0 | 3 | 2 | 1 | 1 | 8 | 3 |
| Post Cycle 1 TEAEs: Grade 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Post Cycle 1 TEAEs: Grade 5 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.
| participants | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 | 0 | 2 | 5 | 3 | 16 | 3 | 1 | 4 | 19 | 5 |
| Post Cycle 1 | 1 | 3 | 4 | 3 | 10 | 3 | 2 | 3 | 17 | 5 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness \[to study drug\] was assessed by the investigator (Yes/No).
| participants | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Related to Study Drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Related to Study Drug | 1 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 1 | 1 |
| nanogram per milliliter (ng/mL) | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose | 9.6 ± 6.0 | 20.7 ± 0.7 | 28.7 ± 6.9 | 45.6 ± 20.4 | 51.6 ± 22.2 | 83.8 ± 13.9 | 80.8 ± 28.4 | 104.2 ± 60.7 |
| ng/mL | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose | 15.9 ± 5.0 | 35.7 ± 5.7 | 58.6 ± 13.9 | 71.2 ± 22.2 | 86.2 ± 29.6 | 160.8 ± 70.4 | 173.6 ± 29.5 | 185.7 ± 119.6 |
The mean Cmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| ng/mL | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 104.0 ± 50.2 |
To determine the impact of food (specifically a high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In this crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. The first 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, the next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. The high-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of the total caloric content.
| ng/mL | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Fed | 62.0 ± 20.4 |
| Fasted | 44.9 ± 14.4 |
| hours | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose | 4.0 (4.0 to 4.0) | 4.0 (4.0 to 4.3) | 4.0 (4.0 to 10.0) | 4.0 (2.0 to 10.0) | 7.0 (2.0 to 24.4) | 4.0 (4.0 to 9.8) | 5.7 (1.0 to 10.2) | 4.0 (4.0 to 7.0) |
| hours | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose | 4.0 (2.0 to 7.0) | 4.1 (2.0 to 7.0) | 4.0 (4.0 to 9.0) | 5.5 (4.0 to 10.0) | 4.0 (1.0 to 10.0) | 7.0 (7.0 to 10.0) | 4.0 (2.0 to 7.0) | 4.5 (1.0 to 7.0) |
The median Tmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| hours | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 4.2 (2.0 to 9.8) |
To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
| hours | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Fed | 7.00 (3.50 to 23.00) |
| Fasted | 7.00 (4.00 to 10.00) |
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
No measurements were reported for this outcome.
Terminal half-life is the time measured for the plasma concentration to decrease by one half.
No measurements were reported for this outcome.
Terminal half-life is the time measured for the plasma concentration to decrease by one half. The mean t1/2 for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| hours | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Terminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 26.5 ± 7.0 |
To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
| nanogram*hour/milliliter (ng*hour/mL) | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose | 58 ± 29.5 | 134 ± 7.2 | 199 ± 40.5 | 302 ± 119.6 | 476 ± 281.1 | 594 ± 118.1 | 1057 ± 570.5 | 719 ± 396.7 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).
| ng*hour/mL | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose | 118 ± 38.3 | 274 ± 41.8 | 477 ± 122.7 | 560 ± 183.1 | 722 ± 265.3 | 1344 ± 565.3 | 1395 ± 315.6 | 1482 ± 935.1 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The mean AUClast for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| ng*hour/mL | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 3626 ± 2565.8 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
| ng*hour/mL | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Fed | 809 ± 372.7 |
| Fasted | 668 ± 280.6 |
Area under the curve from time zero to end of the dosing interval (24 hours) \[AUC (0-tau)\]. The mean AUC (0-tau) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| ng*hour/mL | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Area Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 1863 ± 1096.5 |
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
No measurements were reported for this outcome.
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).
No measurements were reported for this outcome.
AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
No measurements were reported for this outcome.
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
No measurements were reported for this outcome.
Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. The mean CL/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| liter/hour | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Apparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 86.1 ± 42.8 |
Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
No measurements were reported for this outcome.
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. The mean Vz/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| liter | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Apparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 3103 ± 1237.8 |
Volume of distribution: theoretical volume in which total amount of drug would need to be uniformly distributed to produce desired plasma concentration. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Rac at Day 8 = AUC (0-tau) at Day 8 divided by AUC (0-tau) at Day 1.
No measurements were reported for this outcome.
Rac at Day 14/21 = AUC (0-tau) at Day 14/21 divided by AUC (0-tau) at Day 1. The mean Rac for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| ratio | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Accumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 2.5 ± 0.8 |
Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural--logarithm transformed concentration--time profile.
No measurements were reported for this outcome.
Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile.
No measurements were reported for this outcome.
Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile. The mean lambda (z) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.
| 1/hour | PD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days) |
|---|---|
| Terminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose | 0.028 ± 0.0 |
Terminal phase rate constant: absolute value of slope of a linear regression during terminal phase of natural-logarithm transformed concentration-time profile. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Urine PK analysis was performed only in the MTD/RP2D groups (125 mg \[21/28 Days\] and 200 mg \[14/21 Days\]).
| microgram (mcg) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 200 mg QD (14/21 Days) |
|---|---|---|
| Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose | 2191 ± 1404 | 3171 ± 2442 |
The Ae is defined in Outcome Measure 42. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Percent of dose recovered unchanged in urine over the 10 hour collection interval=100\*(Ae divided by dose). Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval.
| percentage of dose | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 200 mg QD (14/21 Days) |
|---|---|---|
| Percent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose | 1.75 ± 1.1 | 1.59 ± 1.2 |
The percent Ae is defined in Outcome Measure 44. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.
No measurements were reported for this outcome.
Number of participants with best response. Complete response (CR): disappearance of all target and non-target lesions. Partial Response (PR): \>=30% decrease in sum of longest diameter (LD) of lesions taking as reference baseline sum LD and no unequivocal progression in non-target lesions. Progressive disease (PD): \>=20% increase in sum of LD of lesions taking as a reference smallest sum of the LD since treatment start, or the appearance of \>=1 new lesion or unequivocal progression of existing non-target lesions. Stable disease (SD): neither shrinkage for PR nor increase for PD taking as reference smallest sum of LD since treatment start. SD was assessed following the first 2 cycles of treatment (\>=2 cycles), 4 cycles of treatment (\>=4 cycles), and 10 cycles of treatment (\>=10 cycles). Participants may be reported in more than 1 category of SD. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
| participants | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| Confirmed CR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Confirmed PR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| SD >=2 Cycles | 1 | 2 | 1 | 1 | 6 | 2 | 1 | 0 | 5 | 3 |
| SD >=4 Cycles | 1 | 2 | 1 | 1 | 3 | 2 | 1 | 0 | 3 | 2 |
| SD >=10 Cycles | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 1 |
| PD | 2 | 1 | 6 | 2 | 13 | 0 | 2 | 3 | 12 | 3 |
| Not Assessable | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue and p-Rb levels (fold decrease) were to be reported.
No measurements were reported for this outcome.
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with respect to PD 0322991 dose.
No measurements were reported for this outcome.
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with PD 0322991 exposure.
No measurements were reported for this outcome.
Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with tumor response.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PD 0332991 25 mg QD (21/28 Days) | — | 3/3 (100%) | 3/3 (100%) |
| PD 0332991 50 mg QD (21/28 Days) | — | 1/3 (33.3%) | 3/3 (100%) |
| PD 0332991 75 mg QD (21/28 Days) | — | 3/7 (42.9%) | 7/7 (100%) |
| PD 0332991 100 mg QD (21/28 Days) | — | 1/3 (33.3%) | 3/3 (100%) |
| PD 0332991 125 mg QD (21/28 Days) | — | 3/22 (13.6%) | 22/22 (100%) |
| PD 0332991 150 mg QD (21/28 Days) | — | 0/3 (0%) | 3/3 (100%) |
| PD 0332991 100 mg QD (14/21 Days) | — | 2/3 (66.7%) | 3/3 (100%) |
| PD 0332991 150 mg QD (14/21 Days) | — | 3/4 (75%) | 4/4 (100%) |
| PD 0332991 200 mg QD (14/21 Days) | — | 4/20 (20%) | 20/20 (100%) |
| PD 0332991 225 mg QD (14/21 Days) | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| HypotensionVascular disorders | 0/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 0/3 | 2/4 | 0/20 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 0/3 | 0/4 | 0/20 | 0/6 |
| Atrial fibrillationCardiac disorders | 0/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 1/3 | 0/4 | 0/20 | 0/6 |
| Cardiac arrestCardiac disorders | 1/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 0/3 | 0/4 | 0/20 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 1/3 | 0/4 | 2/20 | 0/6 |
| ConstipationGastrointestinal disorders | 0/3 | 1/3 | 1/7 | 0/3 | 0/22 | 0/3 | 0/3 | 1/4 | 0/20 | 0/6 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 0/3 | 0/4 | 0/20 | 0/6 |
| Intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 0/7 | 1/3 | 0/22 | 0/3 | 0/3 | 0/4 | 0/20 | 0/6 |
| Oesophageal stenosisGastrointestinal disorders | 0/3 | 0/3 | 0/7 | 0/3 | 0/22 | 0/3 | 1/3 | 0/4 | 0/20 | 0/6 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 0/3 | 0/7 | 1/3 | 0/22 | 0/3 | 0/3 | 1/4 | 0/20 | 0/6 |
| Event | PD 0332991 25 mg QD (21/28 Days) | PD 0332991 50 mg QD (21/28 Days) | PD 0332991 75 mg QD (21/28 Days) | PD 0332991 100 mg QD (21/28 Days) | PD 0332991 125 mg QD (21/28 Days) | PD 0332991 150 mg QD (21/28 Days) | PD 0332991 100 mg QD (14/21 Days) | PD 0332991 150 mg QD (14/21 Days) | PD 0332991 200 mg QD (14/21 Days) | PD 0332991 225 mg QD (14/21 Days) |
|---|---|---|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 2/3 | 4/7 | 3/3 | 8/22 | 3/3 | 0/3 | 0/4 | 12/20 | 3/6 |
| FatigueGeneral disorders | 1/3 | 2/3 | 3/7 | 2/3 | 10/22 | 3/3 | 2/3 | 1/4 | 15/20 | 3/6 |
| PainGeneral disorders | 0/3 | 3/3 | 1/7 | 1/3 | 0/22 | 0/3 | 2/3 | 0/4 | 4/20 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 2/3 | 0/3 | 2/7 | 1/3 | 6/22 | 1/3 | 1/3 | 1/4 | 8/20 | 3/6 |
| LeukopeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/7 | 2/3 | 2/22 | 1/3 | 0/3 | 0/4 | 3/20 | 2/6 |
| ConstipationGastrointestinal disorders | 0/3 | 2/3 | 2/7 | 1/3 | 5/22 | 0/3 | 2/3 | 2/4 | 6/20 | 1/6 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 2/3 | 3/7 | 1/3 | 4/22 | 0/3 | 2/3 | 1/4 | 9/20 | 2/6 |
| FlatulenceGastrointestinal disorders | 0/3 | 0/3 | 1/7 | 2/3 | 2/22 | 0/3 | 2/3 | 0/4 | 3/20 | 0/6 |
| NauseaGastrointestinal disorders | 0/3 | 2/3 | 2/7 | 2/3 | 6/22 | 2/3 | 1/3 | 1/4 | 11/20 | 1/6 |
| VomitingGastrointestinal disorders | 0/3 | 1/3 | 1/7 | 2/3 | 6/22 | 1/3 | 1/3 | 1/4 | 3/20 | 0/6 |
Full Analysis Set (FAS) included all enrolled participants who received at least one dose of study medication.
| Age, Continuous(years) | PD 0332991 (21/28 Days) | PD 0332991 (14/21 Days) | Total |
|---|---|---|---|
| Mean | 53.8 ± 13.1 | 59.9 ± 11.5 | 56.5 ± 12.7 |
| Sex: Female, Male(Participants) | PD 0332991 (21/28 Days) | PD 0332991 (14/21 Days) | Total |
|---|---|---|---|
| Female | 21 | 17 | 38 |
| Male | 20 | 16 | 36 |
The record gives a start of Sep 2004, a primary completion of Jul 2008 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 7 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib